Injection therapy for the treatment of erectile dysfunction: A comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2577-2583

  Shah, P J R ^a   Dinsmore, W ^b   Oakes, R A ^c   Hackett, Geoff ^d  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c Allstoe House   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Alprostadil; Erectile dysfunction; Intracavernosal injection; Phentolamine; Vasoactive intestinal polypeptide

Indexed keywords

PHENTOLAMINE MESYLATE; PROSTAGLANDIN E1; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FLUSHING; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIAPISM; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; SIDE EFFECT;

EID: 35648997466     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X233232     Document Type: Article

References (11)

1. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006;332: 589-92
2. Porst H. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int J Impot Res 2000;12(Suppl 4): S91-100
3. Webber R. Erectile dysfunction. Clin Evid Concise 2005;14: 295-6
4. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil - a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997;9:187-92
5. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Eng J Med 1996;334:873-7
6. Polak JM, Gu J, Mina S, Bloom SR. Vipergic nerves in the penis. Lancet 1981;2:217-19
7. Shirai M, Maki A, Takanami M, et al. Content and distribution of vasoactive intestinal polypeptide (VIP) in cavernous tissue of human penis. Urology 1990;35:360-3
8. Kim NN, Gallanc C, Dhir V. Potentiation of VIP induced relaxation by phentolamine in corpus cavernosum. Int J Impot Res 1998;10:S44
9. Sandhu D, Curless E, Dean J, et al. A double blind placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phentolamine mesilate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res 1999;11:91-7
10. Dinsmore WW, Gingell C, Hackett G, et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesilate in a novel auto-injector system: a multi-centre double blind placebo controlled study. BJU Int 1999;83:274-9
11. Dinsmore WW, Alderdice DK. Vasoactive intestinal polypeptide and phentolamine mesilate in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 1998;81:437-4